Kidney Transplant Rejection - Pipeline Insight, 2026
Description
DelveInsight’s, “Kidney Transplant Rejection - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Kidney Transplant Rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Kidney Transplant Rejection: Overview
Kidney transplant rejection occurs when the recipient’s immune system identifies the donor organ as foreign and initiates an immune response that can compromise graft survival. It may manifest as acute rejection within the first few months, driven by T-cell or antibody-mediated mechanisms, and is a major cause of early graft dysfunction. Chronic rejection develops over time, leading to progressive structural damage such as interstitial fibrosis, tubular atrophy, and transplant glomerulopathy, contributing to long-term graft loss. Less common forms, including hyperacute and accelerated rejection, arise rapidly due to pre-existing antibodies against the donor tissue. Clinically, rejection may present with fever, fatigue, graft-site tenderness, reduced urine output, fluid retention, elevated blood pressure, and rising creatinine levels, reflecting declining kidney function.
Kidney transplant rejection occurs when the immune system identifies the donor organ as foreign, activating T-cell– and antibody-mediated responses. Antibody-mediated rejection (ABMR), driven by donor-specific antibodies and complement activation, is the most common form and leads to vascular injury and chronic damage. T-cell–mediated rejection (TCMR) involves cytotoxic T-cell–driven inflammation and tissue injury, often worsened by immune imbalance. Risk factors include nonadherence to immunosuppression, HLA mismatch, prior rejection, deceased-donor grafts, younger age, and delayed graft function.
Kidney transplant rejection is diagnosed through a combination of clinical assessment, laboratory findings, and confirmatory biopsy, often interpreted using the Banff classification to differentiate acute and chronic injury. An increase in serum creatinine typically triggers biopsy evaluation, which can reveal features of T-cell or antibody-mediated rejection, including tubulitis, inflammatory infiltrates, C4d deposition, and the presence of donor-specific antibodies. Non-invasive approaches such as urine biomarkers and donor-derived cell-free DNA are increasingly used to detect early immune activation. Imaging modalities like contrast-enhanced ultrasound and MRI can further assist by identifying perfusion abnormalities associated with graft dysfunction.
Treatment focuses on rapidly controlling immune activation and is guided by the biopsy-confirmed subtype. T-cell-mediated rejection (TCMR) is usually treated with high-dose corticosteroids, with lymphocyte-depleting therapies considered in steroid-resistant cases. Antibody-mediated rejection (ABMR) requires a combination approach, including antibody removal strategies, intravenous immunoglobulin, and agents targeting B cells or the complement system. In refractory cases, newer biologic therapies are being explored to improve outcomes.
""Kidney Transplant Rejection- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kidney Transplant Rejection pipeline landscape is provided which includes the disease overview and Kidney Transplant Rejection treatment guidelines. The assessment part of the report embraces, in depth Kidney Transplant Rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kidney Transplant Rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Kidney Transplant Rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kidney Transplant Rejection Emerging Drugs
Felzartamab: Biogen
Felzartamab is an investigational monoclonal antibody being developed for the treatment of kidney transplant rejection, particularly antibody-mediated rejection (AMR). It targets and depletes CD38-expressing cells, including plasma cells, plasmablasts, and natural killer cells, which contribute to disease pathology. By reducing pathogenic antibody production and limiting complement activation and microvascular inflammation, it addresses key drivers of graft injury. Felzartamab is currently in Phase III stage of its clinical development.
Tegoprubart: Eledon Pharmaceuticals
Tegoprubart is an investigational immunosuppressive therapy developed by Eledon Pharmaceuticals for the prevention of kidney transplant rejection. It functions as a novel anti-CD40L antibody, targeting the CD40/CD40L costimulatory pathway, which plays a central role in immune activation during allograft rejection. By modulating this pathway, the therapy aims to provide effective immunosuppression with a potentially improved safety profile compared to conventional treatments. Tegoprubart is currently being evaluated in Phase II clinical trials for kidney transplant rejection.
Further product details are provided in the report……..
Kidney Transplant Rejection: Therapeutic Assessment
This segment of the report provides insights about the different Kidney Transplant Rejection drugs segregated based on following parameters that define the scope of the report, such as:
Kidney Transplant Rejection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Kidney Transplant Rejection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kidney Transplant Rejection drugs.
Kidney Transplant Rejection Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Kidney Transplant Rejection: Overview
Kidney transplant rejection occurs when the recipient’s immune system identifies the donor organ as foreign and initiates an immune response that can compromise graft survival. It may manifest as acute rejection within the first few months, driven by T-cell or antibody-mediated mechanisms, and is a major cause of early graft dysfunction. Chronic rejection develops over time, leading to progressive structural damage such as interstitial fibrosis, tubular atrophy, and transplant glomerulopathy, contributing to long-term graft loss. Less common forms, including hyperacute and accelerated rejection, arise rapidly due to pre-existing antibodies against the donor tissue. Clinically, rejection may present with fever, fatigue, graft-site tenderness, reduced urine output, fluid retention, elevated blood pressure, and rising creatinine levels, reflecting declining kidney function.
Kidney transplant rejection occurs when the immune system identifies the donor organ as foreign, activating T-cell– and antibody-mediated responses. Antibody-mediated rejection (ABMR), driven by donor-specific antibodies and complement activation, is the most common form and leads to vascular injury and chronic damage. T-cell–mediated rejection (TCMR) involves cytotoxic T-cell–driven inflammation and tissue injury, often worsened by immune imbalance. Risk factors include nonadherence to immunosuppression, HLA mismatch, prior rejection, deceased-donor grafts, younger age, and delayed graft function.
Kidney transplant rejection is diagnosed through a combination of clinical assessment, laboratory findings, and confirmatory biopsy, often interpreted using the Banff classification to differentiate acute and chronic injury. An increase in serum creatinine typically triggers biopsy evaluation, which can reveal features of T-cell or antibody-mediated rejection, including tubulitis, inflammatory infiltrates, C4d deposition, and the presence of donor-specific antibodies. Non-invasive approaches such as urine biomarkers and donor-derived cell-free DNA are increasingly used to detect early immune activation. Imaging modalities like contrast-enhanced ultrasound and MRI can further assist by identifying perfusion abnormalities associated with graft dysfunction.
Treatment focuses on rapidly controlling immune activation and is guided by the biopsy-confirmed subtype. T-cell-mediated rejection (TCMR) is usually treated with high-dose corticosteroids, with lymphocyte-depleting therapies considered in steroid-resistant cases. Antibody-mediated rejection (ABMR) requires a combination approach, including antibody removal strategies, intravenous immunoglobulin, and agents targeting B cells or the complement system. In refractory cases, newer biologic therapies are being explored to improve outcomes.
""Kidney Transplant Rejection- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kidney Transplant Rejection pipeline landscape is provided which includes the disease overview and Kidney Transplant Rejection treatment guidelines. The assessment part of the report embraces, in depth Kidney Transplant Rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kidney Transplant Rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Kidney Transplant Rejection R&D. The therapies under development are focused on novel approaches to treat/improve Kidney Transplant Rejection.
This segment of the Kidney Transplant Rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kidney Transplant Rejection Emerging Drugs
Felzartamab: Biogen
Felzartamab is an investigational monoclonal antibody being developed for the treatment of kidney transplant rejection, particularly antibody-mediated rejection (AMR). It targets and depletes CD38-expressing cells, including plasma cells, plasmablasts, and natural killer cells, which contribute to disease pathology. By reducing pathogenic antibody production and limiting complement activation and microvascular inflammation, it addresses key drivers of graft injury. Felzartamab is currently in Phase III stage of its clinical development.
Tegoprubart: Eledon Pharmaceuticals
Tegoprubart is an investigational immunosuppressive therapy developed by Eledon Pharmaceuticals for the prevention of kidney transplant rejection. It functions as a novel anti-CD40L antibody, targeting the CD40/CD40L costimulatory pathway, which plays a central role in immune activation during allograft rejection. By modulating this pathway, the therapy aims to provide effective immunosuppression with a potentially improved safety profile compared to conventional treatments. Tegoprubart is currently being evaluated in Phase II clinical trials for kidney transplant rejection.
Further product details are provided in the report……..
Kidney Transplant Rejection: Therapeutic Assessment
This segment of the report provides insights about the different Kidney Transplant Rejection drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Kidney Transplant Rejection
- There are approx. 10+ key companies which are developing the therapies for Kidney Transplant Rejection. The companies which have their Kidney Transplant Rejection drug candidates in the most advanced stage, i.e. Phase III include, Biogen.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Kidney Transplant Rejection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Kidney Transplant Rejection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kidney Transplant Rejection drugs.
Kidney Transplant Rejection Report Insights
- Kidney Transplant Rejection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Kidney Transplant Rejection drugs?
- How many Kidney Transplant Rejection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kidney Transplant Rejection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kidney Transplant Rejection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Kidney Transplant Rejection and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biogen
- Eledon Pharmaceuticals
- Tonix Pharmaceuticals
- Veloxis Pharmaceuticals
- BioPhoenix Co., Ltd.
- Felzartamab
- Tegoprubart
- TNX-1500
- VEL-101
- BPC2003
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Kidney Transplant Rejection: Overview
- Introduction
- Causes
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Kidney Transplant Rejection– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Felzartamab: Biogen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tegoprubart: Eledon Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Inactive Products
- Comparative Analysis
- Kidney Transplant Rejection Key Companies
- Kidney Transplant Rejection Key Products
- Kidney Transplant Rejection- Unmet Needs
- Kidney Transplant Rejection- Market Drivers and Barriers
- Kidney Transplant Rejection- Future Perspectives and Conclusion
- Kidney Transplant Rejection Analyst Views
- Kidney Transplant Rejection Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
